Monthly Archives: May, 2019
New Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of IBS, 2019.
The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology, health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University …
U.S. FDA Approves Reintroduction of Tegaserod (Zelnorm) for Some Women with IBS with Constipation (IBS-C)
Over a month ago, the U.S Food and Drug Administration (FDA) approved the reintroduction of tegaserod (brand name Zelnorm), an oral medication for irritable bowel syndrome with constipation (IBS-C) to the U.S., only for women without risk factors for or history of cardiovascular conditions. Tegaserod, a selective serotonin type 4 receptor partial agonist was available …
Online Study: Gastrointestinal Unhelpful Thinking Scale (GUTS) Development Study, Swinburne University, Australia, May 2019
The following study currently seeking men and women at least 18 years old in any country with chronic gastrointestinal conditions is a followup to online studies posted here on August 12, 2017 and June 9, 2018. The 2017 and 2018 studies are now closed to new volunteers. The current study has received institutional ethical approval. …
IFFGD 2019 National Advocacy Event in Washington DC Scheduled for June 24-25, 2019
The International Foundation for Gastrointestinal Disorders (IFFGD), a U.S.-based not-for-profit organization for IBS and other gastrointestinal disorders has announced its annual event in Washington, DC for June 24-25, 2019. Traditionally, during this event delegation of IFFGD staff, gastroenterology professionals and affected people and their families meets with members of Congres to raise awareness and advocate …
IBS IMPACT 